The realm of rare diseases, often termed orphan diseases, presents a complex landscape that affects millions globally. Despite the classification of these conditions as rare—affecting a small segment of the population—they collectively impact an estimated 300 to 400 million individuals, with only about 5% having approved treatments. As the world’s attention pivots towards enhancing healthcare accessibility, particularly in light of the WHO’s impending Global Action Plan for Rare Diseases, it is imperative to analyze how regulatory frameworks, health technology assessments (HTAs), and pricing policies in key regions, namely the UK, EU, and US, influence the development and availability of orphan medicines.
Defining Rare Diseases
Rare diseases are defined by their low prevalence, which in the European Union is categorized as affecting fewer than 5 in 10,000 individuals, while in the United States, the threshold is fewer than 200,000 patients. Approximately 85% of these conditions are ultra-rare, impacting fewer than one in a million people. The rarity of these diseases poses significant challenges for research and treatment development, leading to disproportionately high costs associated with orphan drug production. This situation necessitates a blend of public funding and commercial incentives to motivate progress in the sector.
Regulatory Incentives: A Double-Edged Sword
To stimulate the development of orphan treatments, both the US and EU have established regulatory incentives. The EU offers 10 years of market exclusivity, protocol assistance, and various national research and development incentives, while the US provides 7 years of exclusivity, tax credits, grants, and priority reviews. However, the efficacy of these incentives is often undermined by disparate HTA and pricing processes at the national level, which can cause delays in patient access to innovative treatments.
Global Health Priorities and Policy Developments
Recent recognition by the World Health Assembly of rare diseases as a global health priority underscores the need for equitable access to timely and affordable treatments. The WHO’s Global Action Plan aims to address these disparities, creating an opportunity to evaluate the current state of orphan medicine development and access.
Disparities in Access Across Regions
An analysis of orphan drug designations from 2001 to 2024 reveals a significant disparity between the US and EU. The US FDA approved over three times as many orphan medicines compared to the European Medicines Agency (EMA). This discrepancy can be attributed to the more stringent evidential requirements imposed by the EMA and the variability in HTA processes across EU member states, which can further complicate patient access to approved treatments.
The UK’s Commitment to Rare Disease Framework
In the UK, the introduction of a Rare Diseases Framework five years ago aimed to create a unified strategy for improving the quality of life for those affected by rare conditions. Extended to 2026, the framework emphasizes enhancing access to specialist care and treatments. Recent initiatives include a White Paper outlining a new framework for supporting the development and delivery of rare disease therapies, which aims to balance patient needs with regulatory rigor.
EU Pharmaceutical Legislation Reform
In late 2025, the EU Council and Parliament agreed on reforms to the pharmaceutical legislation, which will alter the regulatory framework for orphan medicines. The proposed changes include reducing the baseline market exclusivity period and introducing new obligations for manufacturers regarding supply quantity. Additionally, the establishment of the Joint Clinical Assessment (JCA) aims to create a harmonized approach to clinical assessments, though challenges remain in integrating diverse patient populations and ensuring equitable access.
The Role of the United States in Rare Disease Development
The United States has been a frontrunner in rare disease research, largely due to the Orphan Drug Act of 1983 and substantial federal funding from the NIH. However, recent policy shifts, including the Inflation Reduction Act and Most Favored Nation pricing reforms, could impact investment decisions and the commercial viability of orphan medicines. The tightening of federal funding and potential disincentives for manufacturers pursuing multiple indications may hinder the momentum gained in orphan drug development.
Fostering Equitable Access to Treatments
To promote equitable access to cost-effective therapies, it is vital to adopt broader value perspectives that encompass societal benefits. Innovative payment models, such as outcomes-based agreements, can help link payment structures to treatment effectiveness, ultimately supporting affordability while maintaining incentives for development.
Conclusion
The evolving landscape of rare disease policies presents both challenges and opportunities for equitable access to orphan medicines. While recent developments indicate progress, significant disparities remain in treatment availability across regions. Continued advocacy for comprehensive frameworks, innovative payment models, and collaborative efforts among stakeholders is essential for ensuring that patients with rare diseases receive the timely and effective treatments they deserve.
- Key Takeaways:
- Rare diseases collectively affect hundreds of millions, yet only a small percentage have approved treatments.
- Regulatory incentives vary significantly between the US and EU, impacting drug approval rates.
- The WHO’s Global Action Plan aims to enhance access to rare disease therapies globally.
- The UK and EU are making strides in policy reforms to improve patient access.
- Innovative payment models could help bridge gaps in affordability and access.
Read more → www.ohe.org